{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:15:46Z","timestamp":1792628146997,"version":"4.5.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,2,22]],"date-time":"2017-02-22T00:00:00Z","timestamp":1487721600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s40265-017-0711-7","type":"journal-article","created":{"date-parts":[[2017,2,22]],"date-time":"2017-02-22T12:30:11Z","timestamp":1487766611000},"page":"473-479","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":273,"title":["Nusinersen: First Global Approval"],"prefix":"10.1007","volume":"77","author":[{"given":"Sheridan M.","family":"Hoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,22]]},"reference":[{"issue":"11","key":"711_CR1","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s11940-014-0316-3","volume":"16","author":"D Castro","year":"2014","unstructured":"Castro D, Iannaccone ST. Spinal muscular atrophy: therapeutic strategies. Curr Treat Options Neurol. 2014;16(11):316.","journal-title":"Curr Treat Options Neurol."},{"key":"711_CR2","doi-asserted-by":"publisher","unstructured":"Farrar MA, Park SB, Vucic S, et al. Emerging therapies and challenges in spinal muscular atrophy. Ann Neurol. 2016. doi: 10.1002\/ana.24864 .","DOI":"10.1002\/ana.24864"},{"key":"711_CR3","unstructured":"US National Library of Medicine. Genetics Home Reference: spinal muscular atrophy. 2017. https:\/\/ghr.nlm.nih.gov\/ . Accessed 16 Jan 2017."},{"issue":"1","key":"711_CR4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S, Burglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80(1):155\u201365.","journal-title":"Cell."},{"issue":"10","key":"711_CR5","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1038\/nbt1016-1002","volume":"34","author":"K Garber","year":"2016","unstructured":"Garber K. Big win possible for Ionis\/Biogen antisense drug in muscular atrophy. Nat Biotech. 2016;34(10):1002\u20133.","journal-title":"Nat Biotech."},{"key":"711_CR6","unstructured":"Biogen Inc. SPINRAZA (nusinersen) injection, for intrathecal use: US prescribing information. 2016. http:\/\/www.fda.gov\/ . Accessed 9 Jan 2017."},{"key":"711_CR7","unstructured":"US Food and Drug Administration. FDA approves first drug for spinal muscular atrophy. 2016. http:\/\/www.fda.gov . Accessed 17 Jan 2017."},{"key":"711_CR8","unstructured":"Biogen. US FDA approves Biogen\u2019s SPINRAZA\u2122 (nusinersen), the first treatment for spinal muscular atrophy. 2016. https:\/\/www.biogen.com\/ . Accessed 9 Feb 2017."},{"key":"711_CR9","unstructured":"Biogen. Biogen and Ionis Pharmaceuticals announce SPINRAZA (nusinersen) meets primary endpoint at interim analysis of phase 3 CHERISH study in later-onset spinal muscular atrophy. 2016. http:\/\/www.biogen.com\/ . Accessed 26 Jan 2017."},{"key":"711_CR10","unstructured":"US FDA Center for Drug Evaluation and Research. Medical review(s). 2016. http:\/\/www.fda.gov\/ . Accessed 24 Jan 2017."},{"issue":"10063","key":"711_CR11","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","volume":"388","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Chiriboga CA, Vajsar J, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet. 2017;388(10063):3017\u201326.","journal-title":"Lancet."},{"key":"711_CR12","unstructured":"US FDA Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s). 2016. http:\/\/www.fda.gov\/ . Accessed 24 Jan 2017."},{"issue":"10","key":"711_CR13","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","volume":"86","author":"CA Chiriboga","year":"2016","unstructured":"Chiriboga CA, Swoboda KJ, Darras BT, et al. Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy. Neurology. 2016;86(10):890\u20137.","journal-title":"Neurology."},{"key":"711_CR14","unstructured":"Biogen. Biogen and Ionis Pharmaceuticals report nusinersen meets primary endpoint at interim analysis of phase 3 ENDEAR study in infantile-onset spinal muscular atrophy. 2016. http:\/\/www.biogen.com\/ . Accessed 17 Jan 2017."},{"key":"711_CR15","unstructured":"Biogen. New data presented at World Muscle Society Congress support potential benefit of investigational treatment nusinersen in spinal muscular atrophy. 2016. http:\/\/www.biogen.com\/ . Accessed 26 Jan 2017."},{"issue":"9\u201310","key":"711_CR16","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.nmd.2014.06.417","volume":"24","author":"B Darras","year":"2014","unstructured":"Darras B, Chiriboga C, Swoboda K, et al. Results of a phase 2 study of ISIS-SMNRx in children with spinal muscular atrophy [abstract no. G.O.18]. Neuromuscul Disord. 2014;24(9\u201310):920.","journal-title":"Neuromuscul Disord."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0711-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-017-0711-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0711-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T11:07:30Z","timestamp":1498388850000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-017-0711-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,22]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["711"],"URL":"https:\/\/doi.org\/10.1007\/s40265-017-0711-7","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,22]]}}}